NEURONAL VIABILITY: AN INDISPENSABLE INDICATOR OF DRUG SAFETY & TOXICITY
Evaluating the impacts of drug candidates on cell viability are required for moving therapeutic candidates into the clinic, but distinguishing between mechanisms of death can prove challenging. It is crucial that CNS-targeting drugs do not compromise cell health and that drugs that do not target the CNS do not have off-target effects.
Our Ready-2-Go Assay Service uses multiplexed dyes to simultaneously measure apoptosis and viability in human, iPSC-derived glutamatergic neurons.
KEY FEATURES
Uses human, iPSC-derived neurons
Multiplexed measurements of apoptosis and cell viability
Only 6-8 weeks from assay to report
Option to bundle R2G Services or transition to Custom Services
AVOID SPECIES DIFFERENCES WITH HUMAN, iPSC-DERIVED NEURONS
The use of animal models or immortalized cell lines limits clinical translatability. We use human, iPSC-derived neurons to help bridge the gap between the bench and clinic.
RELATED READY-2-GO SERVICES
Browse related Ready-2-Go assay offerings. For custom assays, check out our Custom Services.
R2G NEURONAL MITOCHONDRIAL HEALTH
Multiplexed readouts of mitochondrial health.
Learn more
R2G NEURITE OUTGROWTH & NEURITE NETWORK DYNAMICS
Quantification of neurite outgrowth and changes in established neurite networks using human, iPSC-derived neurons.
Learn more
R2G MICROGLIA PHAGOCYTOSIS
Measure uptake of a fluorescent bacterial bioparticle by human, iPSC-derived microglia.
Learn more